Sabby Management, LLC Altimmune, Inc. Transaction History

Sabby Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$7.84 - $14.22 $108,192 - $196,236	-13,800 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$9.93 - $33.26 $137,034 - $458,988	13,800 New	13,800 $182,000
Q1 2020 May 15, 2020	SELL	$1.69 - $3.8 $75,804 - $170,449	-44,855 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.53 - $2.15 $4,738 - $6,658	3,097 Added 7.42%	44,855 $85,000
Q3 2019 Nov 15, 2019	BUY	$1.95 - $2.66 $14,728 - $20,090	7,553 Added 22.08%	41,758 $81,000
Q2 2019 Aug 14, 2019	BUY	$2.19 - $3.4 $74,908 - $116,297	34,205 New	34,205 $81,000
Q1 2019 May 15, 2019	SELL	$2.54 - $4.54 $604,319 - $1.08 Million	-237,921 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$1.72 - $7.24 $409,224 - $1.72 Million	237,921 New	237,921 $490,000

208

39.5M

1.94M

1.38M

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $315M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.